Evidence map›Paper›PMID 31382581›Full record

ReviewCancers2019

MiT Family Translocation Renal Cell Carcinoma: from the Early Descriptions to the Current Knowledge.

Anna Caliò, Diego Segala, Enrico Munari, Matteo Brunelli, Guido Martignoni

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed, 1 pooled it
13.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 1 synthesis or guideline pooled it, 131 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Cancers · 2026
    Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Anna CaliòDepartment of Diagnostic and Public Health, Section of Pathology, University of Verona, Verona 37134, Italy.
Diego SegalaDepartment of Pathology, Pederzoli Hospital, Peschiera del Garda 37019, Italy.
Enrico MunariDepartment of Pathology, Sacro Cuore Hospital, Negrar 37024, Italy.
Matteo BrunelliDepartment of Diagnostic and Public Health, Section of Pathology, University of Verona, Verona 37134, Italy.
Guido MartignoniDepartment of Diagnostic and Public Health, Section of Pathology, University of Verona, Verona 37134, Italy. guido.martignoni@univr.it.
University of Verona · ITCasa di Cura Villa Garda · ITOspedale Sacro Cuore Don Calabria · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The new category of MiT family translocation renal cell carcinoma has been included into the World Health Organization (WHO) classification in 2016. The MiT family translocation renal cell carcinoma comprises Xp11 translocation renal cell carcinoma harboring

Indexed as

11) translocation renal cell carcinomaFISHMiT family translocation renal cell carcinomat(6TFE3TFEBTFEB-amplified renal cell carcinomaXp11 translocation renal cell carcinoma

Identifiers

PMID31382581
PMCPMC6721505
OpenAlexW2964951353

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.